Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review (Q37786051)

23 August 2017

title

Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review (English)

1 reference

23 August 2017

Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review (English)

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

8 July 2024

0 references

1 reference

1 reference

5

Katherine Esposito

1 reference

23 August 2017

3

Giuseppe Bellastella

1 reference

23 August 2017

1

Dario Giugliano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822821

8 July 2024

2

Maria Ida Maiorino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822821

8 July 2024

4

Paolo Chiodini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822821

8 July 2024

language of work or name

1 reference

6 September 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0168822710003967?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

https://api.elsevier.com/content/article/PII:S0168822710003967?httpAccept=text/plain

8 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Diabetes Research and Clinical Practice

8 July 2024

published in

1 reference

23 August 2017

volume

92

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

1-10

1 reference

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

8 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Barriers to insulin initiation: the translating research into action for diabetes insulin starts project

8 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

8 July 2024

Insulin analogues

5

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

8 July 2024

The market in diabetes

6

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

8 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

8 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes

8 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses

8 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

8 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials

8 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

8 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

8 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

8 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Meta-analysis in clinical trials

8 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Quantifying heterogeneity in a meta-analysis

8 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group

8 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

8 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?

8 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

8 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

8 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

8 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

8 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes

8 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

8 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride

8 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents

8 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy

8 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

8 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

8 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies

8 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility

8 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

8 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group

8 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week

8 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

8 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

8 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial

8 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

8 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).

8 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

8 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

8 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy

8 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs

8 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs

8 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

8 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

8 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

8 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

8 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes

8 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

8 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.

8 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.

8 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

8 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study

8 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

8 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.

8 July 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine

8 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial

8 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial).

8 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.

8 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study

8 July 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.

8 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Recruitment to a clinical trial improves glycemic control in patients with diabetes

8 July 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Three-year efficacy of complex insulin regimens in type 2 diabetes

8 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

8 July 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.DIABRES.2010.08.006

8 July 2024

Identifiers

1 reference

23 August 2017

1 reference